# Thymulin: Research Overview — Lazarus Research Peptides > A literature summary of Thymulin (serum thymic factor / FTS), a zinc-dependent nonapeptide thymic hormone: zinc-activity dependence, T-lymphocyte differentiation, NF-kB anti-inflammatory action, and neuroendocrine axis. A nine-amino-acid peptide produced exclusively by thymic epithelial cells — biologically active only when bound to one zinc ion per molecule. ## The short version Thymulin is a small hormone made only in the thymus — specifically, only in the epithelial cells that line the thymic interior. It is a nonapeptide, meaning nine amino acids long. What makes it unusual is that it cannot do anything biologically unless it is bound to a single zinc ion. The zinc-free form (called the apopeptide) is inert. Bind zinc and the resulting Zn-thymulin complex adopts a specific 3D shape and drives T-lymphocyte differentiation [12]. The research record is largely preclinical. Most evidence comes from animal and cell models, often using gene-therapy approaches to restore circulating thymulin or to deliver it to specific tissues [9][8]. There are no human clinical trials of exogenous thymulin. This page reports what was studied, in which models, without any dosing recommendation. ## What it is Thymulin, historically called serum thymic factor (FTS, from the French *facteur thymique serique*), is a linear nonapeptide with the sequence pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn. The N-terminal residue is a cyclized (pyroglutamate) form of glutamine, written as <Glu. Biological activity depends entirely on binding one zinc(II) ion in an equimolecular (1:1) ratio; the zinc-bound form adopts a conformation detectable by NMR [12]. A key disambiguation: Thymulin is **not** Thymosin Alpha-1 (a 28-amino-acid immunomodulatory thymic polypeptide with a completely different sequence and mechanism), nor is it thymalin (a bovine thymic complex sometimes sold as a separate supplement), nor thymosin beta-4 or its fragment (an actin-binding peptide from a different protein family). These are distinct molecules. ## How it works Thymulin's primary biological role is to promote T-lymphocyte differentiation within the thymus and to modulate peripheral immune-cell function. The zinc-dependent conformation is required for receptor binding [12]. Beyond classical thymic immunology, thymulin participates in a bidirectional thymus-neuroendocrine axis: the anterior pituitary and other neuroendocrine tissues regulate thymic thymulin secretion, while thymulin itself acts as a hypophysiotropic peptide — it signals back to the pituitary and to CNS structures [11]. Anti-inflammatory activity has also been documented. In LPS-treated mice, thymulin reduced plasma pro-inflammatory cytokines, suppressed NF-kB and SAPK/JNK signaling, and downregulated inducible heat-shock proteins — effects comparable to dietary fat-soluble antioxidants [10]. These anti-inflammatory properties make it a subject of gene-therapy investigation in inflammatory lung disease [8]. ## What the research shows *Zinc-activity coupling.* The 1994 review established the complete sequence (pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn), the strict 1:1 zinc-binding requirement, and the conformation-detection evidence by NMR. It also documented that serum thymulin activity falls with zinc deficiency and is corrected by zinc supplementation in animals and humans — positioning serum thymulin as a sensitive indicator of zinc status [12]. *Neuroendocrine axis.* The 2009 review synthesized the evidence for thymulin as a hypophysiotropic peptide, detailed its regulation by the neuroendocrine system, and described the anti-inflammatory and analgesic activity demonstrated in the rat brain, including durable expression from an adenoviral thymulin gene-therapy vector injected intracranially [11]. *Anti-inflammatory mechanism.* In male BALB/c mice given LPS, daily thymulin for two weeks before endotoxin challenge reduced plasma pro-inflammatory cytokines and inducible HSP72/HSP90alpha, modulated NF-kB and JNK signaling, and enhanced the effect of an IKK inhibitor on IKK activation — placing thymulin mechanistically in the NF-kB anti-inflammatory pathway [10]. *Therapeutic biology and gene therapy.* A 2014 review of thymulin physiology documented neuroendocrine regulation of thymulin secretion and described the cloning of a synthetic biologically active analog (metFTS) into regulatable adenovectors; delivery of this construct to athymic nude mice restored circulating thymulin and prevented hormonal and reproductive abnormalities caused by thymodeficiency [9]. *Inhaled gene therapy for asthma.* A single intratracheal dose of thymulin-expressing plasmids in mucus-penetrating nanoparticles, given *after* allergic asthma was fully and stably established, normalized chronic lung inflammation, pulmonary fibrosis, and mechanical dysregulation at 20 days in mice — demonstrating near-complete therapeutic reversal via anti-inflammatory and antifibrotic mechanisms [8]. ## Where it fits, cautions & safety Thymulin has no community anecdote base compiled in this desk's sources; the section below draws entirely from the literature record. Literature-grounded cautions: - *Entirely preclinical with sparse human data.* No published human clinical trials of exogenous thymulin exist; human studies have used synthetic analogs (nonathymulin) rather than the native nonapeptide, and several human studies are dated. - *Zinc dependence complicates interpretation.* Because activity requires zinc, reported effects are entangled with the zinc status of any system studied; outcomes labeled "thymulin effects" may partly reflect zinc availability. - *Conflation risk.* Consumer sources frequently conflate thymulin with Thymosin Alpha-1 and with thymalin (a bovine thymic complex); these are chemically and pharmacologically distinct molecules and should not be treated as interchangeable. - *Unknown human pharmacokinetics and dosing.* Half-life, bioavailability, and standardized human dosing are not characterized in the public literature. - *Not FDA-approved.* Thymulin is not approved by the FDA for any indication; it is handled as a research chemical for laboratory use only. ## Where it fits in immune research Thymulin occupies the hormonal layer of this desk. Where [Thymosin Alpha-1](/thymosin-alpha-1) is a well-characterized immunostimulatory peptide with a clinical trail extending to large human RCTs, and [KPV](/kpv) operates as a local anti-inflammatory signal at the tissue level, Thymulin is the thymus gland's own output hormone — a regulator of T-cell production that also speaks back to the brain. Its zinc-dependence makes it a unique probe of the thymus-zinc-immunity triangle, and its emerging gene-therapy applications in asthma are among the most novel findings in the peptide field [8]. See the [comparison page](/compare) for how it lines up. ![Thymulin research illustration](/images/thymulin.webp) --- A literature digest of peer-reviewed immune and thymic peptide research — citations in hand, no products on offer.